drugset / Trial / NCT04575922
Nivolumab+Ipilimumab+RT in MSS mCRC
Phase 2
Active not recruiting
32 enrolled
Massachusetts General Hospital
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to study the effects of the combination of ipilimumab, nivolumab, and radiation therapy in people with metastatic microsatellite stable colorectal cancer. This research study involves the following drugs and interventions: * Ipilimumab * Nivolumab * Radiation Therapy
Timeline
- Start
- 2020-10-05
- Primary completion
- 2023-12
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |